Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Profound Medical Corp PROF


Primary Symbol: T.PRN

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed... see more

Recent & Breaking News (TSX:PRN)

Profound Medical Announces Closing of Offerings

GlobeNewswire September 20, 2019

Profound Medical Announces Pricing of Offerings

GlobeNewswire September 13, 2019

Profound Medical Announces Proposed Offerings of Units

Canada NewsWire September 12, 2019

Profound Medical Announces Proposed Offerings of Units

GlobeNewswire September 12, 2019

Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO®

GlobeNewswire August 16, 2019

Accomplished Financial Executive, Steve Forte, Joins Profound Medical's Board

GlobeNewswire August 15, 2019

Profound Medical Announces Second Quarter 2019 Financial Results

GlobeNewswire August 14, 2019

Profound Medical to Present at the Canaccord Genuity 39th Annual Growth Conference

GlobeNewswire July 31, 2019

Profound Medical to Release Second Quarter 2019 Financial Results on August 14 - Conference Call to Follow

GlobeNewswire July 30, 2019

Profound Medical Sells First TULSA-PRO® System in Japan

GlobeNewswire July 9, 2019

Profound Medical Annual and Special Meeting of Shareholders Voting Results

GlobeNewswire June 13, 2019

Profound Medical Announces First Quarter 2019 Financial Results

GlobeNewswire May 6, 2019

Profound Medical to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 23, 2019

Profound Medical to Release First Quarter 2019 Financial Results on May 6 - Conference Call to Follow

GlobeNewswire April 17, 2019

Foundation Chairman Shares Focused Ultrasound Growth at Inaugural Global Investor Conference

PR Newswire April 15, 2019

Profound Medical Analyst & Investor Day Agenda

GlobeNewswire April 8, 2019

Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer

GlobeNewswire April 4, 2019

Profound Medical Announces Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 7, 2019

Profound Medical to Present at the Cowen and Company 39th Annual Health Care Conference

GlobeNewswire March 5, 2019

Save the Date: Profound Medical to Host Inaugural Analyst & Investor Day on April 11

GlobeNewswire February 28, 2019